New Study Shows Listeria Vaccine for Cervical Cancer Found Safe

October 18, 2007 - Researchers testing a vaccine based on the live bacteria Listeria, in women with advanced cervical cancer found it to be safe.
The Lovaxin C vaccine being developed by Advaxis Inc., is intended to treat cervical cancer and head and neck cancers that result from the human papilloma virus (HPV). This marked the first time the vaccine had been treated in humans.
Advaxis reported treating fifteen patients in three dosage groups with thirty-minute 250 ml infusions of Lovaxin C at three-week intervals. Patients were observed for a total of 111 days. With the exception of two women, all patients had had either stage IVb advanced, recurrent, or progressive cervical cancer.
Although efficacy was not a primary focus of the trial, efficacy findings were obtained. Of the seven stable patients, three had reductions in their tumor mass subsequent to treatment. While most lesions increased in size, tumor reduction was seen in a number of lesions and two tumors disappeared completely.
For more information: www.advaxis.com